The website is targeted at consumers looking to buy drugs without using insurance, meaning that most purchases would not count toward patients' insurance deductibles. US President Donald Trump on ...

Sullivan is professor of health economics and policy and former dean of pharmacy at the University of Washington. Hansen is professor of health economics and policy and chair of the Department of ...

Mr. Shirky, a vice provost at New York University, has been helping faculty members and students adapt to digital tools since 2015. Back in 2023, when ChatGPT was still new, a professor friend had a ...

Amgen Inc. (AMGN) reported strong Q4 2025 results and provided full-year 2026 guidance that was above Street expectations. The company is managing losses of exclusivity on several large products quite ...

Robert A. Bradway: Okay. Thank you, Casey, and good afternoon, everyone. Thank you for joining us today. Today, we'll cover full-year results for 2025 and provide a preview of what to expect from us ...

For decades, the United States has led the world in developing groundbreaking medications that allow patients to live longer and healthier lives. Despite these contributions, American families pay ...

Americans will soon be able buy some prescription drugs at discounted cash prices through TrumpRx, a new self-pay website launching Thursday as part of President Donald Trump’s broader push to lower ...

Experts say it’ll help a narrow group of people, citing “no clear advantage for most people” to use the platform The Trump administration announced that its discount drug platform, TrumpRx, will ...

WASHINGTON >> President Donald Trump on Thursday unveiled TrumpRx.gov, a website meant to offer consumers access to discounted prescription medicines and a central pillar of his efforts to lower drug ...

Biotech company Amgen (NASDAQ:AMGN) beat Wall Street’s revenue expectations in Q4 CY2025, with sales up 8.6% year on year to $9.87 billion. The company’s full-year revenue guidance of $37.7 billion at ...

Amgen is hopeful that Phase III data will cement the validity of its recently approved widened label for cholesterol-lowering drug Repatha (evolocumab). In August 2025, the US Food and Drug ...

Wegovy might be getting more competition soon. During the first half of 2025, Wegovy and Zepbound, two weight loss drugs, ranked among the top 10 best-selling medicines worldwide. And given current ...